Medical advances in hepatitis D therapy

• Verfasst von: Vogt, Amelie [VerfasserIn]
• Verfasst von: Wohlfart, Sabrina [VerfasserIn]
• Verfasst von: Urban, Stephan [VerfasserIn]
• Verfasst von: Mier, Walter [VerfasserIn]
• Titel: Medical advances in hepatitis D therapy
• Titelzusatz: molecular targets
• Verf.angabe: Amelie Vogt, Sabrina Wohlfart, Stephan Urban and Walter Mier
• E-Jahr: 2022
• Jahr: 16 September 2022
• Umfang: 12 S.
• Fussnoten: Gesehen am 15.11.2022
• Titel Quelle: Enthalten in: International journal of molecular sciences
• Ort Quelle: Basel : Molecular Diversity Preservation International, 2000
• Jahr Quelle: 2022
• Band/Heft Quelle: 23(2022), 18, Artikel-ID 10817, Seite 1-12
• ISSN Quelle: 1422-0067
• ISSN Quelle: 1661-6596
• DOI: doi:10.3390/ijms231810817
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: antivirals
• Sach-SW: farnesyl transferase
• Sach-SW: hepatitis B
• Sach-SW: hepatitis D
• Sach-SW: Hepcludex
• Sach-SW: viral entry mechanisms
• K10plus-PPN: 1822485258

Abstract

An approximate number of 250 million people worldwide are chronically infected with hepatitis B virus, making them susceptible to a coinfection with hepatitis D virus. The superinfection causes the most severe form of a viral hepatitis and thus drastically worsens the course of the disease. Until recently, the only available therapy consisted of interferon-α, only eligible for a minority of patients. In July 2020, the EMA granted Hepcludex conditional marketing authorization throughout the European Union. This first-in-class entry inhibitor offers the promise to prevent the spread in order to gain control and eventually participate in curing hepatitis B and D. Hepcludex is an example of how understanding the viral lifecycle can give rise to new therapy options...